The APHRODITE trial

Phase II trial of radiotherapy dose escalation for non-surgical management of early rectal cancer. ISRCTN16158514. Funded by @yorkshirecancer, run by @LeedsCTRU

[The APHRODITE trial @aphrodite_trial]

Slight correction: one of our amazing recruiting teams managed to inform and recruit a patient very last minute, so we actually finished at 119 patients 😊🤩

[The APHRODITE trial @aphrodite_trial]

That's a wrap 🎉

APHRODITE has finished recruitment: 118 early stage rectal cancer patients randomised 2:1 between 62Gy and 50.4Gy #radonc

We will have primary endpoint data (cCR rates @ 6 months) next summer 🌞

Many, many thanks to all trial sites, PIs, and patients 😍

[Leeds Radiotherapy Research 💙 @LeedsRTresearch]

Also in our #YorkshireDay series.

The @aphrodite_trial, spearheaded by @cancerphysicist aims to find out if a higher radiotherapy dose will give greater benefit to patients with #bowelcancer

@LeedsCTRU @LTHRadiotherapy

[The APHRODITE trial @aphrodite_trial]

We’ve recruited 100 patients! 🎉🎉🎉
Many congratulations to Dr Muirhead and team at @OUHospitals for getting us to this lovely round number - only a few to go now 😳
#radonc #rectalcancer

[David Sebag (he/him) 🇺🇦💙 @MontefioreD]

Excellent presentation demonstrating highly quality assured radiotherapy in the ⁦@yorkshirecancer⁩ funded APHRODITE organ preservation rectal cancer trial including boost delivery ⁦@LeedsCTRU⁩ ⁦@cancerphysicist⁩ ⁦@UniversityLeeds⁩ ⁦@LeedsHospitals⁩

[Ane Appelt @cancerphysicist]

Dose planning results from our @aphrodite_trial trial presented by Debra Howard @RTTQA_UK 😊
The trial use a novel mesorectal volume with SIB, implemented in a multicentre setting. Luckily, that’s been feasible, with almost identical OAR doses in the two arms #ESTRO24 #radonc

[The APHRODITE trial @aphrodite_trial]

We're on 90 patients! 🎉 Getting close now ...
@yorkshirecancer @LeedsRTresearch

[The APHRODITE trial @aphrodite_trial]

Happy New Year!
Yesterday, colleagues @TheChristieNHS recruited patient 83 (out of 104) 🎉 🎉
And last week @yorkshirecancer approved a £176k extension to our trial grant, ensuring that we can complete recruitment and FU as planned for all patients 🥳🥳🥳
@LeedsCTRU #radonc

[David Sebag (he/him) 🇺🇦💙 @MontefioreD]

The ⁦@UniversityLeeds⁩ ⁦@aphrodite_trial⁩ trial is testing a smarter kinder radiotherapy treatment in early rectal cancer. Funded by ⁦@yorkshirecancer⁩ and run by ⁦@LeedsCTRU⁩ it is benefiting patients on both sides of the Pennines. https://t.co/mTviDLQp7D

[Yorkshire Cancer Research @yorkshirecancer]

It's fantastic to see research funded by the charity making a difference to lives across the country 💙

[The APHRODITE trial @aphrodite_trial]

More great media coverage for APHRODITE today! The trial is a testament to the close ongoing collaboration between @LeedsCTRU and @LeedsRTresearch - and would not have happened without essential funding and support from @yorkshirecancer
@UniversityLeeds
https://t.co/GGPYAHHFwU

[RTTQA @RTTQA_UK]

Great to see a patient from the @aphrodite_trial bravely sharing their story. It is a real pleasure to provide the quality assurance for this trial and we are delighted that 75/104 patients have now been recruited. Well done team!

[The APHRODITE trial @aphrodite_trial]

We hope that many more patients with rectal cancer, like Tom, can benefit from radiotherapy in the future, and avoid surgery and a stoma. 75 out of 104 patients recruited - not far to go now! #radonc #rectalcancer

[The APHRODITE trial @aphrodite_trial]

Brilliant to see @Independent highlighting the APHRODITE trial - and to read Tom Critchley's story as a patient on the trial. Tom, thank you so much for helping other cancer patients by contributing to clinical research 😍
https://t.co/JVqzD8cpIw

[Alexandra Smith @alexandra_leeds]

It’s such a great feeling when your trial finally hits its recruitment groove. Never easy but always worth the effort @cancerphysicist 👍👏💪

[The APHRODITE trial @aphrodite_trial]

July was our best month yet for recruitment!

We recruited ✨7 patients✨ across our 11 trial sites, brining us to a total of 63 patients (out of 104 planned)

A special shout-out to @TheChristieNHS, where @ClaireLArthur & colleagues recruited 3 patients!

#rectalcancer #radonc

[Edward JD Webb @Beardy_Econ]

Thanks to everyone who came to discuss our working paper on the interim @aphrodite_trial patient preference results! We look at the trade-offs patients having radiotherapy for rectal cancer make between cure/side effects - relevant for clinical dose-escalation studies #hesg2023

[Ane Appelt @cancerphysicist]

Breaking my holiday (semi-)silence for these exciting (preliminary) results from the @aphrodite_trial patient preference sub-study - exploring patient treatment preferences
in the setting of non-operative management of #rectalcancer
#radonc

[Edward JD Webb @Beardy_Econ]

I'm going to be sliding into your SMDMs this morning, presenting interim results from the @aphrodite_trial patient preference project @socmdm #esmdm23

[Ane Appelt @cancerphysicist]

Excellent to see our @EFOMP_org work on the involvement of #medphys in clinical trials expertly presented by @NatLAbbott on the #ESTRO23 stage
(And I definitely appreciated the @aphrodite_trial mention!)